公开(公告)号：US20240410013A1

公开(公告)日：2024-12-12

申请号：US18653413

申请日：2024-05-02

Applicant: Genentech, Inc.

Inventor： Habib HAMIDI ,  Mahrukh Huseni ,  Romain Francois Banchereau

IPC: C12Q1/6886 ,  A61K39/00 ,  A61K39/395

Abstract: The invention provides methods and compositions for classifying kidney cancer (e.g., RCC, e.g., an inoperable, locally advanced, or metastatic RCC); methods and compositions for treating kidney cancer in a patient, for example, by administering a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) and a VEGF antagonist (e.g., bevacizumab) to the patient. Also provided are compositions, pharmaceutical compositions, kits, and articles of manufacture for use in classifying and treating kidney cancer in a patient.